Point-of-care test for cervical cancer in LMICs

Sulma I. Mohammed, Wen Ren, Lisa Flowers, Bartek Rajwa, Carla J. Chibwesha, Groesbeck P. Parham, Joseph M.K. Irudayaraj

Research output: Contribution to journalArticlepeer-review


Cervical cancer screening using Papanicolaou's smear test has been highly effective in reducing death from this disease. However, this test is unaffordable in low- and middle-income countries, and its complexity has limited wide-scale uptake. Alternative tests, such as visual inspection with acetic acid or Lugol's iodine and human papillomavirus DNA, are sub-optimal in terms of specificity and sensitivity, thus sensitive and affordable tests with high specificity for on-site reporting are needed. Using proteomics and bioinformatics, we have identified valosin-containing protein (VCP) as differentially expressed between normal specimens and those with cervical intra-epithelial neoplasia grade 2/3 (CIN2/CIN3+) or worse. VCP-specific immunohistochemical staining (validated by a point-of-care technology) provided sensitive (93%) and specific (88%) identification of CIN2/CIN3+ and may serve as a critical biomarker for cervical-cancer screening. Future efforts will focus on further refinements to enhance analytic sensitivity and specificity of our proposed test, as well as on prototype development.

Original languageEnglish (US)
Pages (from-to)18787-18797
Number of pages11
Issue number14
StatePublished - 2016
Externally publishedYes


  • Africa
  • Cancer
  • Cervical
  • LMIC
  • Point-of-care

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Point-of-care test for cervical cancer in LMICs'. Together they form a unique fingerprint.

Cite this